TARS - NASDAQ
Tarsus Pharmaceuticals, Inc.
$61.00
+3.8%Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
At a Glance
Live SnapshotTarsus Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Tarsus Pharmaceuticals, Inc. Income Statement
TARS • NASDAQ
| Tarsus Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
451.4M | 183M | 17.4M | 25.8M | 57M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(30.7M) | (12.8M) | (1.6M) | (955K) | (2.1M) | (246K) | (74K) | (1K) | |
420.7M | 170.1M | 15.9M | 24.9M | 55M | -246K | -74K | -1K | |
OPERATING INCOME | ||||||||
(491.6M) | (290.7M) | (159M) | (87.6M) | (67.1M) | (26.7M) | (4.2M) | (1.3M) | |
(427.3M) | (237.3M) | (108.7M) | (44.9M) | (25.4M) | (7.9M) | (1.1M) | (448K) | |
(64.3M) | (53.4M) | (50.3M) | (42.6M) | (41.7M) | (18.8M) | (3.2M) | (901K) | |
-71M | -120.6M | -143.2M | -62.7M | -12.2M | -27M | -4.3M | -1.4M | |
PRE-TAX INCOME | ||||||||
(8.9M) | (7.4M) | (3.2M) | (2.1M) | (0.0) | (188K) | (40K) | (0.0) | |
6.8M | 7.6M | 7.1M | 1.4M | 36K | 0.0 | 0.0 | 0.0 | |
6.6M | 5M | 7.3M | 617K | -1.6M | 173K | -371K | 32K | |
-64.4M | -115.6M | -135.9M | -62.1M | -13.8M | -26.8M | -4.7M | -1.3M | |
NET INCOME | ||||||||
(2.1M) | (0.0) | (0.0) | -4K | (55K) | (1K) | (1K) | (1K) | |
-66.4M | -115.6M | -135.9M | -62.1M | -13.8M | -26.8M | -4.7M | -1.3M |
SEC Filings
TARS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 18, 2026 | February 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 06, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your TARS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.